NCT06109948 - Study to Assess the Safety, Tolerability, PK and PD of ABX1100 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

HealthyLate Onset Pompe Disease

Interventions

DRUG

ABX1100 injection for IV infusion

Centyrin protein-siRNA conjugate

DRUG

Placebo injection for IV infusion

placebo saline injection

Trial Locations (5)

RECRUITING

Lysosomal and Rare Disorders Research and Treatment Center, Inc, Fairfax

RECRUITING

Washington University School of Medicine, St Louis

RECRUITING

UCI, Orange

RECRUITING

MAGIC clinic, Calgary

RECRUITING

McMaster University, Hamilton